Detail akcie Xencor online

Business Summary: Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Xencor Inc revenues decreased 86% to $4.5M. Net loss increased from $48.4M to $128.9M. Revenues reflect Milestone segment decrease from $14.5M to $0K, Royalties segment decrease of 76% to $4.4M. Higher net loss reflects (Loss) gain on equity securities, net decrease from $941K (income) to $51.9M (expense), Research and Development - Balancing increase of 16% to $59.6M (expense).